Top Tweets for #Vaccinetech

2025 in Review: A Year of Momentum & A Bright Path Ahead As 2025 draws to a close, we at BioVaxys are proud to reflect on a year of meaningful progress and strategic advancement. A major milestone was the successful integration of the powerful DPX™ platform into the heart of our BioVaxys business — strengthening our foundation and unlocking exciting new opportunities. We’ve also been deliberate about building a world-class team of advisors and directors who bring deep expertise and fresh perspective to help us fully develop and realize the true value of our remarkably undervalued DPX intellectual property portfolio. Looking ahead, 2026 is shaping up to be a pivotal year. We’re energized by the ongoing out-licensing and research collaboration discussions currently underway, and we anticipate a very active period of business development — with the exciting prospect of booking our first royalty revenue. We’re incredibly grateful for the continued support of our shareholders, partners, and team as we execute on this vision. Read the full 2025 year-end update here: https://t.co/ym25zqLNlJ Here’s to closing out 2025 strong — and to an even more impactful 2026 ahead! — James Passin, CEO